Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell lines

Suzuki,Toshihiro; Sirimangkalakitti,Nachanun; Baba,Asami; Toyoshima‑Nagasaki,Ryoko; Enomoto,Yuna; Saito,Naoki; Ogasawara,Yuki

doi:10.3892/or.2022.8281

Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell lines

Authors:
- Toshihiro Suzuki
- Nachanun Sirimangkalakitti
- Asami Baba
- Ryoko Toyoshima‑Nagasaki
- Yuna Enomoto
- Naoki Saito
- Yuki Ogasawara
View Affiliations

Affiliations: Department of Analytical Biochemistry, Meiji Pharmaceutical University, Tokyo 204‑8588, Japan, Department of Pharmaceutical Chemistry, Meiji Pharmaceutical University, Tokyo 204‑8588, Japan
Published online on: February 10, 2022 https://doi.org/10.3892/or.2022.8281
Article Number: 70

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer has been reported to be the leading cause of cancer‑related mortality worldwide. Cisplatin combination chemotherapy is a standard therapeutic strategy for patients with non‑small cell lung cancer (NSCLC) lacking driver mutations. However, the development of cisplatin resistance is a major obstacle to effective cancer treatment. The cellular mechanisms underlying cisplatin resistance have been previously revealed to be multifunctional. Accordingly, mechanistic analysis and the development of novel therapeutic strategies for cisplatin‑resistant NSCLC are urgently required. The present study mainly focused on the DNA repair mechanisms in cisplatin‑resistant NSCLC cells. Additionally, the effects of an Ecteinascidin (Et) derivative on cisplatin‑resistant cell lines were examined, by using a cisplatin‑resistant NSCLC cell line subjected to nucleotide excision repair (NER) pathway alterations. The results revealed that xeroderma pigmentosum group F‑complementing protein (XPF) mRNA expression was strongly associated with cisplatin resistance in cisplatin‑resistant NSCLC cell lines. XPF silencing significantly restored the sensitivity of cisplatin‑resistant PC‑14/CDDP cells to the drug. A potent anticancer effect of Et was observed in the cisplatin‑resistant cell line (PC‑14/CDDP), in which the NER pathway was altered. On the whole, these findings revealed that the expression levels of NER pathway‑related genes, including XPF, may have potential as biomarkers of cisplatin resistance. It was also suggested that Et may be a very promising compound for the development of novel anticancer drugs for the treatment of cisplatin‑resistant lung cancer.

View Figures

View References

1	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
2	Takano N, Ariyasu R, Koyama J, Sonoda T, Saiki M, Kawashima Y, Oguri T, Hisakane K, Uchibori K, Nishikawa S, et al: Improvement in the survival of patients with stage IV non-small-cell lung cancer: Experience in a single institutional 1995–2017. Lung Cancer. 131:69–77. 2019. View Article : Google Scholar : PubMed/NCBI
3	Saito M, Shiraishi K, Kunitoh H, Takenoshita S, Yokota J and Kohno T: Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 107:713–720. 2016. View Article : Google Scholar : PubMed/NCBI
4	Suzuki T, Nishio K and Tanabe S: The MRP family and anticancer drug metabolism. Curr Drug Metab. 2:367–377. 2001. View Article : Google Scholar : PubMed/NCBI
5	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
6	Gilson P, Drouot G, Witz A, Merlin JL, Becuwe P and Harlé A: Emerging roles of DDB2 in cancer. Int J Mol Sci. 20:51682019. View Article : Google Scholar : PubMed/NCBI
7	Bowden NA: Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
8	Spivak G: Nucleotide excision repair in humans. DNA Repair (Amst). 36:13–18. 2015. View Article : Google Scholar : PubMed/NCBI
9	Zhang Y, Cao J, Meng Y, Qu C, Shen F and Xu L: Overexpression of xeroderma pigmentosum group C decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin. Oncol Lett. 15:6336–6344. 2018.PubMed/NCBI
10	Stevens EV, Nishizuka S, Antony S, Reimers M, Varma S, Young L, Munson PJ, Weinstein JN, Kohn EC and Pommier Y: Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther. 7:10–18. 2008. View Article : Google Scholar : PubMed/NCBI
11	Pajuelo-Lozano N, Bargiela-Iparraguirre J, Dominguez G, Quiroga AG, Perona R and Sanchez-Perez I: XPA, XPC, and XPD modulate sensitivity in gastric cisplatin resistance cancer cells. Front Pharmacol. 9:11972018. View Article : Google Scholar : PubMed/NCBI
12	Zewail-Foote M and Hurley LH: Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove. J Med Chem. 42:2493–2497. 1999. View Article : Google Scholar : PubMed/NCBI
13	Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, et al: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 7:961–966. 2001. View Article : Google Scholar : PubMed/NCBI
14	Herrero AB, Martin-Castellanos C, Marco E, Gago F and Moreno S: Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 66:8155–8162. 2006. View Article : Google Scholar : PubMed/NCBI
15	Tsujimoto M, Lowtangkitcharoen W, Mori N, Pangkruang W, Putongking P, Suwanborirux K and Saito N: Chemistry of ecteinascidins. Part 4: Preparation of 2′-N-acyl ecteinascidin 770 derivatives with improved cytotoxicity profiles. Chem Pharm Bull (Tokyo). 61:1052–1064. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sirimangkalakitti N, Chamni S, Charupant K, Chanvorachote P, Mori N, Saito N and Suwanborirux K: Chemistry of renieramycins. 15. Synthesis of 22-O-ester derivatives of jorunnamycin A and their cytotoxicity against non-small-cell lung cancer cells. J Nat Prod. 79:2089–2093. 2016. View Article : Google Scholar : PubMed/NCBI
17	Suwanborirux K, Amnuoypol S, Plubrukarn A, Pummangura S, Kubo A, Tanaka C and Saito N: Chemistry of renieramycins. Part 3.(1) isolation and structure of stabilized renieramycin type derivatives possessing antitumor activity from Thai sponge Xestospongia species, pretreated with potassium cyanide. J Nat Prod. 66:1441–1446. 2003. View Article : Google Scholar : PubMed/NCBI
18	Daikuhara N, Tada Y, Yamaki S, Charupant K, Amnuoypol S, Suwanborirux K and Saito N: Chemistry of renieramycins. Part 7: Renieramycins T and U, novel renieramycin-ecteinascidin hybrid marine natural products from Thai sponge Xestospongia sp. Tetrahedron Lett. 50:4276–4278. 2009. View Article : Google Scholar
19	Rinehart KL, Holt TG, Fregeau NL, Stroh JG, Keifer PA, Sun F, Li LH and Martin DG: Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J Org Chem. 55:4512–4515. 1990. View Article : Google Scholar
20	Morikage T, Ohmori T, Nishio K, Fujiwara Y, Takeda Y and Saijo N: Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res. 53:3302–3307. 1993.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Chen SH and Chang JY: New insights into mechanisms of cisplatin resistance: From tumor cell to microenvironment. Int J Mol Sci. 20:41362019. View Article : Google Scholar : PubMed/NCBI
23	Le VH, Inai M, Williams RM and Kan T: Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics. Nat Prod Rep. 32:328–347. 2015. View Article : Google Scholar : PubMed/NCBI
24	Suwanborirux K, Charupant K, Amnuoypol S, Pummangura S, Kubo A and Saito N: Ecteinascidins 770 and 786 from the Thai tunicate Ecteinascidia thurstoni. J Nat Prod. 65:935–937. 2002. View Article : Google Scholar : PubMed/NCBI
25	Yokoya M, Toyoshima R, Suzuki T, Le VH, Williams RM and Saito N: Stereoselective total synthesis of (−)-renieramycin T. J Org Chem. 81:4039–4047. 2016. View Article : Google Scholar : PubMed/NCBI
26	Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T and Saijo N: The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP). Jpn J Cancer Res. 84:83–92. 1993. View Article : Google Scholar : PubMed/NCBI
27	Suzuki T, Nishio K, Sasaki H, Kurokawa H, Saito-Ohara F, Ikeuchi T, Tanabe S, Terada M and Saijo N: cDNA cloning of a short type of multidrug resistance protein homologue, SMRP, from a human lung cancer cell line. Biochem Biophys Res Commun. 238:790–794. 1997. View Article : Google Scholar : PubMed/NCBI
28	Nishio K, Nakamura T, Koh Y, Suzuki T, Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin Oncol. 11:109–115. 1999. View Article : Google Scholar : PubMed/NCBI
29	Jones M, Beuron F, Borg A, Nans A, Earl CP, Briggs DC, Snijders AP, Bowles M, Morris EP, Linch M and McDonald NQ: Cryo-EM structures of the XPF-ERCC1 endonuclease reveal how DNA-junction engagement disrupts an auto-inhibited conformation. Nat Commun. 11:11202020. View Article : Google Scholar : PubMed/NCBI
30	Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA and Madhusudan S: ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecol Oncol. 153:416–424. 2019. View Article : Google Scholar : PubMed/NCBI
31	Cierna Z, Miskovska V, Roska J, Jurkovicova D, Pulzova LB, Sestakova Z, Hurbanova L, Machalekova K, Chovanec M, Rejlekova K, et al: Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. BMC Cancer. 20:172020. View Article : Google Scholar : PubMed/NCBI
32	Wang M, Li E, Lin L, Kumar AK, Pan F, He L, Zhang J, Hu Z and Guo Z: Enhanced activity of variant DNA polymerase β (D160G) contributes to cisplatin therapy by impeding the efficiency of NER. Mol Cancer Res. 17:2077–2088. 2019. View Article : Google Scholar : PubMed/NCBI
33	Jian J, Li S, Liu LZ, Zhen L, Yao L, Gan LH, Huang YQ and Fang N: XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway. Int J Mol Med. 46:201–210. 2020. View Article : Google Scholar : PubMed/NCBI
34	Li M, Chen R, Ji B, Fan C, Wang G, Yue C and Li G: Contribution of XPD and XPF polymorphisms to susceptibility of non-small cell lung cancer in high-altitude areas. Public Health Genomics. 24:189–198. 2021. View Article : Google Scholar : PubMed/NCBI